New CEO for the next level

Spica’s new CEO, Jeff Abbey, is regarded as highly experienced. According to Spica, his appointment marks a decisive turning point, as the Antwerpen-based company plans to expand the use of its proprietary Macrophage Fingerprinting Platform beyond oncology to other chronic conditions.

Most recently, Abbey served as CEO of RNatives, Inc., where he has now taken on the role of Chairman of the Board. Before that, he was Chief Operating Officer and Chief Business Officer at ImmunOs Therapeutics, where he oversaw operations and corporate development and secured a clinical collaboration with Merck. He began his career as CEO at Argos Therapeutics, which, under his leadership, grew from a start-up into a NASDAQ-listed company.

Abbey considers Spica to be at a pivotal stage in its development:: “While the industry has historically struggled with broad, non-specific myeloid treatments that cause systemic toxicities, Spica has unlocked true cellular precision. Our proprietary Macrophage Fingerprinting Platform allows us to identify the right target, in the right patient population, for the right indication – delivering the right treatment to reverse chronic disease. I look forward to working closely with our exceptional scientific team, board, and investors to unlock the immense therapeutic and commercial value of this platform.”

Spica was founded on pioneering research from Aarhus University and Southern Denmark University and is backed by a syndicate of leading life science investors, including Bioqube Ventures, Flanders Future Tech Fund (managed by PMV), and Qbic.